Jianfa Xinxing Venture Capital
建发新兴投资
Elsewhere's corpus does not cover Jianfa Xinxing Venture Capital (also rendered as C&D Emerging Investment) — the entity appears in the index with no descriptive material attached, and the retrieved coverage is all about Qiming Venture Partners' portfolio news rather than this fund. There's nothing sourced here on its founding, size, strategy, or backers, so we won't guess. The results below are the closest related material available.
AI-generated — may contain errors, please verify.
Coverage
BlueRun Ventures' Angel Project Tashi Zhihang Closes $455M Pre-A Round to Build Robots That "Actually Work and Actually Ship" | BlueRun Family
Let China's Embodied Intelligence Take the World Stage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
Qiming Venture Partners co-leads Zenitar's nearly 600 million yuan Series C round
late-stage clinical biotech company
Andon Therapeutics Raises Over 400 Million Yuan in Series C Funding to Accelerate Phase III Clinical Trials for Revolutionary Pan-Anemia Drug
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
Tashi Zhihang Closes $122 Million Angel+ Round | BlueRun Portfolio
Building Trustworthy Super Embodied Intelligence Systems
"Tashi Intelligent Navigation" Closes $122 Million Angel+ Round, Linear Capital Continues to Double Down | Linear Portfolio
Actively recruiting top technical talent from around the world.
Qiming Venture Partners' 16th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
China's high-quality companies have reached a valuation level that's become genuinely attractive.
From PhD to "Foreman": Building a Robot Bricklayer, Paid for by Middle Eastern Tycoons | Linear Capital Portfolio Company
One robot replaces ten skilled workers, with efficiency up 14-fold
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Anlink Bio Completes $42 Million Series A Round to Accelerate Global Development of Bispecific Antibodies and ADC Pipeline
Achieving a rapid transition from preclinical to clinical stages.
BlueRun Ventures Leads AllinkBio's $42 Million Series A Round | BlueRun Ventures
Accelerating Global Development of Bispecific Antibodies and ADC Products
Accelerated R&D and Commercialization of Frontier Products: Medical Devices, Digital Services, and New Brands Go Global | Rongbao
As the year draws to a close and a new one begins, the pace never lets up.
Baseus Technology Completes Series A+ Round to Build Moat Through Design Innovation and R&D
User-centric, practical, and beautiful.
A Fund Moving Against the Tide, Riding the Pulse of the Era丨Entering the Game
Please keep welcoming the "heretical."
AI Medical Device Company "Silicon Based Bionics" Raises Over 800 Million Yuan in Three C-Round Tranches, Led by Source Code Capital
China's first CGM company to receive regulatory approval and achieve mass production without requiring finger-prick calibration
